Japan Approves Astellas’ HIF-PH Inhibitor, AbbVie’s Venclexta, Tecentriq’s Breast Cancer Use and More

September 24, 2019
The Ministry of Health, Labor and Welfare (MHLW) approved a long list of new drugs and indications on September 20, including Astellas Pharma’s first-in-class renal anemia drug roxadustat and Chugai Pharmaceutical’s Tecentriq (atezolizumab) as the first I/O therapy for breast...read more